New Oral Antiviral Medications for COVID-19
What Clinicians Need to Know About the
New Oral Antiviral Medications for COVID-19
COCA Call, January 12, 2022
The emergency use authorizations (EUAs) for the new oral antiviral medications molnupiravir and Paxlovid™ (nirmatrelvir/ritonavir) supplement current therapeutic efforts to decrease hospitalizations and prevent severe COVID-19 and death.
During this COCA Call, presenters from the Centers for Disease Control and Prevention (CDC), Office of the Assistant Secretary for Preparedness and Response, U.S. Food and Drug Administration (FDA), and the National Institutes of Health (NIH) describe the recent EUAs and NIH treatment guidelines, patient prioritization, and resources for healthcare providers.
Subject matter experts will review when to prescribe antiviral medications including patient assessment, how to have a risk-benefit discussion to address patient questions or concerns, and how to prioritize patients if medications are in short supply.
The recording is available for viewing on the COCA Call webpage. The presentation deck is included.
COCA Call Objectives:
At the conclusion of the session, the participant will be able to accomplish the following—
- Cite background information on the topic covered during the presentation.
- Discuss CDC’s role in the topic covered during the presentation.
- Describe the topic’s implications for clinicians.
- Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.
Presenters:
Lauri Hicks, DO
Captain, US Public Health Service
Chief Medical Officer, COVID-19 Response
Director, Office of Antibiotic Stewardship
Division of Healthcare Quality Promotion
Centers for Disease Control and Prevention
Colin Shepard, MD
CDC Liaison to the Assistant Secretary for Preparedness and Response (ASPR)
Center for Preparedness and Response
Centers for Disease Control and Prevention
Stephanie Troy, MD
Senior Medical Officer
Division of Antivirals
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Aimee Hodowanec, MD
Senior Medical Officer
Division of Antivirals
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Alice K. Pau, PharmD
Executive Secretary, NIH COVID-19 Treatment Guidelines Panel
Staff Scientist (Clinical)
Clinical Pharmacy Specialist
Division of Clinical Research
National Institute of Allergy & Infectious Diseases
National Institutes of Health
For information about this update or other clinical issues, or to send your feedback, please contact us at coca@cdc.gov
- CDC Clinician Outreach and Communication Activity Facebook page—connect with COCA on Facebook
- Clinician Outreach and Communication Activity—resources for healthcare providers
- COCA RSS Feed—subscribe to be notified of conference calls, updates, and CDC guidance for health providers
- Crisis & Emergency Risk Communication Training—training program that draws from lessons learned during public health emergencies, and incorporates best practices from the fields of risk and crisis communication
Health Alert Network—CDC’s primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories.
